Synaptojanin-1 Protein

Synaptojanin-1 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Synaptojanin-1 Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Synaptojanin-1</td>
</tr>
<tr>
<td class="label">Gene Encoding</td>
<td>SYNJ1</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O43491</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~170 kDa (isoform 1)</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Presynaptic terminal, endosomes</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Inositol 5-phosphatase family</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">5-phosphatase modulators</td>
<td>Small molecules</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-SYNJ1</td>
</tr>
<tr>
<td class="label">[Autophagy](/entities/autophagy) enhancers</td>
<td>Rapamycin</td>
</tr>
</table>

Introduction

Synaptojanin 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Structure

Synaptojanin-1 is a large multi-domain protein:

• N-terminal Sac1 domain: Phosphatidylinositol-4-phosphatase activity
• Central 5-phosphatase domain: PIP2/PIP3 hydrolysis
• C-terminal proline-rich region: Protein-protein interactions

...

Synaptojanin-1 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Synaptojanin-1 Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Synaptojanin-1</td>
</tr>
<tr>
<td class="label">Gene Encoding</td>
<td>SYNJ1</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O43491</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~170 kDa (isoform 1)</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Presynaptic terminal, endosomes</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Inositol 5-phosphatase family</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">5-phosphatase modulators</td>
<td>Small molecules</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-SYNJ1</td>
</tr>
<tr>
<td class="label">[Autophagy](/entities/autophagy) enhancers</td>
<td>Rapamycin</td>
</tr>
</table>

Introduction

Synaptojanin 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Structure

Synaptojanin-1 is a large multi-domain protein:

• N-terminal Sac1 domain: Phosphatidylinositol-4-phosphatase activity
• Central 5-phosphatase domain: PIP2/PIP3 hydrolysis
• C-terminal proline-rich region: Protein-protein interactions

Multiple isoforms exist through alternative splicing.

Normal Function

Synaptojanin-1 is essential for synaptic vesicle recycling:

Phosphoinositide Metabolism

• Dephosphorylates PI(4,5)P2 to PI4P
• Controls membrane lipid composition
• Regulates endocytic proteins

Synaptic Vesicle Recycling

• Critical for clathrin uncoating
• Functions after vesicle fission
• Maintains vesicle pool size

Endosomal Function

• Regulates endosomal trafficking
• Controls lysosomal function
• Participates in autophagy

Role in Disease

Parkinson's Disease

• SYNJ1 variants are PD risk factors
• May affect [α-synuclein](/proteins/alpha-synuclein) clearance
• Contributes to lysosomal dysfunction

ALS/FTD

• SYNJ1 mutations found in ALS/FTD cases
• Leads to synaptic dysfunction
• Affects RNA granule clearance

Epilepsy

• SYNJ1 variants associated with epileptic phenotypes
• Alters neuronal excitability

Therapeutic Targeting

Key Publications

PMID: 25818833(https://pubmed.ncbi.nlm.nih.gov/25818833/) - SYNJ1 PD: "SYNJ1 variants and Parkinson's disease risk"

PMID: 27193190(https://pubmed.ncbi.nlm.nih.gov/27193190/) - SYNJ1 function: "Synaptojanin-1 in synaptic vesicle recycling"

PMID: 29022662(https://pubmed.ncbi.nlm.nih.gov/29022662/) - SYNJ1 ALS: "SYNJ1 mutations in ALS/FTD"

PMID: 33168845(https://pubmed.ncbi.nlm.nih.gov/33168845/) - SYNJ1 endosomes: "SYNJ1 and endosomal function in [neurons](/entities/neurons)"

Background

The study of Synaptojanin 1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[@synaptojaninc]: Synaptojanin-1 haploinsufficiency and neurodegenerative disease. PMID: 31289234(https://pubmed.ncbi.nlm.nih.gov/31289234/)

See Also

• SYNJ1 Gene
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-pathology)
• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosome-neurodegeneration)
• [Synaptic Vesicle Trafficking Pathway](/mechanisms/synaptic-vesicle-trafficking-pathway)

External Links

• [UniProt: SYNJ1](https://www.uniprot.org/uniprot/O43491)
• [PDB: SYNJ1 domains](https://www.ebi.ac.uk/pdbe/search/pdb?search_term=SYNJ1)
• [NCBI Protein: SYNJ1](https://www.ncbi.nlm.nih.gov/protein/O43491)

Synaptic Vesicle Recycling

Synaptojanin-1 plays a critical role in synaptic vesicle endocytosis. After neurotransmitter release, synaptic vesicles must be recycled to maintain synaptic transmission. Synaptojanin-1 functions as a phosphoinositide phosphatase that dephosphorylates PI(4,5)P₂ and PI(3,4,5)P₃, essential for unclathing synaptic vesicles from the plasma membrane.

Endocytic Cycle

[@refilling]: Refilling: Neurotransmitters are loaded into recycled

Interaction with Other Proteins

• Dynamin I: Works wit- Parkin: Ubiquitinates synaptojanin-1 for degradation

Animal Models

Knockout Studies

• Synaptojanin-1 knockout mice show embryonic lethality
• Conditional knockouts exhibit sever- Impaired synaptic vesicle recycling observed
• Accumulation of clathrin-coated vesicles

Transgenic Models

• PD-associated mutations cause dominant phenotypes
• Alpha-synuclein co-expression enhances pathology
• Rescue experiments demonstrate therapeutic potential

Therapeutic Implications

Parkinson's Disease

• SYNJ1 mutations linked to early-onset PD
• Restoring synaptojanin-1 function as therapeutic strategy
• Gene therapy approaches under investigation
• Small molecule phosphatase activators in development

Other Neurological Disorders

• Epilepsy: Altered synaptic vesicle dynamics
• Autism: Synaptic homeostasis defects
• Schizophrenia: Dopamine system involvement